See more : IXICO plc (IXI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Clever Leaves Holdings Inc. (CLVRW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Clever Leaves Holdings Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eureka Design Public Company Limited (UREKA.BK) Income Statement Analysis – Financial Results
- Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Income Statement Analysis – Financial Results
- Doro AB (publ) (DORO.ST) Income Statement Analysis – Financial Results
- HITIQ Limited (HIQ.AX) Income Statement Analysis – Financial Results
- ATEX Resources Inc. (ATX.V) Income Statement Analysis – Financial Results
Clever Leaves Holdings Inc. (CLVRW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cleverleaves.com
About Clever Leaves Holdings Inc.
Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.42M | 17.80M | 15.37M | 12.12M | 7.83M | 0.00 |
| Cost of Revenue | 10.86M | 13.47M | 8.57M | 4.70M | 4.73M | 99.00K |
| Gross Profit | 6.56M | 4.33M | 6.81M | 7.41M | 3.10M | -99.00K |
| Gross Profit Ratio | 37.64% | 24.33% | 44.29% | 61.18% | 39.60% | 0.00% |
| Research & Development | 1.14M | 1.72M | 1.55M | 1.01M | 0.00 | 0.00 |
| General & Administrative | 17.99M | 27.82M | 38.40M | 29.83M | 34.98M | 4.75M |
| Selling & Marketing | 2.04M | 1.90M | 3.80M | 2.58M | 3.18M | 417.00K |
| SG&A | 20.03M | 29.71M | 42.19M | 32.41M | 38.16M | 5.31M |
| Other Expenses | 0.00 | 2.06M | 1.77M | 1.85M | 1.48M | 0.00 |
| Operating Expenses | 21.17M | 33.49M | 45.51M | 34.26M | 39.64M | 5.31M |
| Cost & Expenses | 33.01M | 46.96M | 54.07M | 38.96M | 44.37M | 5.41M |
| Interest Income | 0.00 | 2.70M | 6.82M | 4.46M | 2.68M | 390.00K |
| Interest Expense | 46.00K | 2.70M | 6.82M | 4.46M | 2.68M | 0.00 |
| Depreciation & Amortization | 2.85M | 3.67M | 3.51M | 3.59M | 1.48M | 99.00K |
| EBITDA | -16.80M | -35.80M | -35.19M | -23.26M | -41.72M | -5.31M |
| EBITDA Ratio | -96.48% | -144.33% | -225.63% | -203.91% | -454.35% | 0.00% |
| Operating Income | -15.59M | -29.16M | -38.70M | -26.85M | -36.54M | -5.41M |
| Operating Income Ratio | -89.53% | -163.82% | -251.72% | -221.56% | -466.43% | 0.00% |
| Total Other Income/Expenses | -4.14M | -15.00M | -5.98M | 951.00K | -9.34M | 13.15M |
| Income Before Tax | -19.73M | -72.46M | -44.68M | -36.68M | -45.88M | 7.74M |
| Income Before Tax Ratio | -113.27% | -407.05% | -290.63% | -302.67% | -585.70% | 0.00% |
| Income Tax Expense | 68.00K | -6.35M | 950.00K | 4.74M | 2.25M | -126.00K |
| Net Income | -17.90M | -66.10M | -45.63M | -41.41M | -48.13M | 7.36M |
| Net Income Ratio | -102.77% | -371.35% | -296.81% | -341.78% | -614.37% | 0.00% |
| EPS | -11.42 | -51.65 | -53.29 | -49.93 | -184.77 | 0.00 |
| EPS Diluted | -11.42 | -51.65 | -53.29 | -49.93 | -184.77 | 0.00 |
| Weighted Avg Shares Out | 1.57M | 1.28M | 856.34K | 829.43K | 260.49K | 0.00 |
| Weighted Avg Shares Out (Dil) | 1.57M | 1.28M | 856.34K | 829.43K | 260.49K | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports